Back to Journal

SM Journal of Reproductive Health & Infertility

Menopause Characterization, Menarche and Fertility among Rural Females of Shimla (Himachal Pradesh)

[ ISSN : 3067-9753 ]

Abstract Citation Introduction Materials and Methods Results Discussion Conclusions References
Details

Received: 06-Sep-2016

Accepted: 26-Oct-2016

Published: 31-Oct-2016

Krishna Sharma, Mayuk Bansal, Shruti Chopra and Maninder Kaur

Department of Anthropology, Panjab University, India

Corresponding Author:

Krishan Sharma, Department of Anthropology, Panjab University, Chandigarh-160014, India; E-mail: kdsharmaanthro@gmail.com; kdsharmalibra@yahoo.co.in, Tel: 091 9417092610

Keywords

Menarche, menopause, climacteric symptoms, livebirths

Abstract

Background: Menopause marks the cessation of reproduction. Menopause rating scales have been used to measure health-related quality of life among aging women. Menopause, menarche and number of live births play important roles in the life history of women.

Objectives: To study the prevalence and pattern of various menopausal characteristics and association of age of menopause with age of menarche and number of livebirths.

Methods: The study was based on cross-sectional data of 75 postmenopausal rural women and also secondary data from published sources to study trends.

Results: Mean age at menarche was 14.23 yrs. and mean age at menopause was 45.35 yrs. About 85% of women had reported some climacteric symptom. Joint/muscle pain was the most commonly reported symptom (66.7%).Women that had early menarche had lower number of live births than those who had later menarche. Women with the intermediate fertility category having 4-5 livebirths had later age of menopause than women having less than three livebirths.

Conclusion: Early and late ages at menarche were associated with early and late ages of menopause, respectively. Fertility performance of women also seemed to be associated with menarche and menopause ages. Indian women have lower mean age at menopause than European and South Asian women while so such difference was evident for age at menarche. Menopausal symptoms had little effect on sexual functioning than other concerns.

Citation

Sharma K, Bansal M, Chopra S and Kaur M. Menopause Characterization, Menarche and Fertility among Rural Females of Shimla (Himachal Pradesh). SM J Reprod Health Infertil. 2016;1(1):1005.

Introduction

Menopause marks the important universal developmental marker of the aging process among women. The natural menopause marks the end of woman’s reproductive capacity as it results in permanent cessation of menstruation and ovulation. It is a physiological event and at the individual level is explained by depletion of the oocyte hypothesis [1,2]. The origin of menopause among women well before they die unlike non-human primates like chimpanzees and baboons has been explained on the basis of non-adaptive and adaptive theories [3,4,5]. Earlier fertility termination evolved in humans as a consequence of other evolutionary changes that made late births increasingly risky [6].

Age at menopause is confirmed by 12 months consecutive absence of menstrual period after the last final menstrual period. This is preceded by perimenopausal phase when menstrual cycles become irregular and interrupted by amenorrhoea. In the Western countries, the menopause transition occurs on an average at 46 years with a range from 34-54 years [7]. The mean/median age for menopause varies among-and within-human populations world over; occurring during the late/ mid 40s to 52 years of age [8,9]. The number of oocytes is fixed at the beginning of life and differences in the rate of depletion or deterioration would lead to individual differences. Several factors have been identified as independent sources of differences in age at menopause, which include genetics, Body Mass Index (BMI), reproductive and hormonal status [10]. There has been secular trend in age at menopause which has increased during the last 25 years due to changes in socioeconomic and lifestyle factors [11-16] Factors like oral contraception and smoking are other reported correlates of the timing of natural menopause [17-19]. Indian women have been reported to have menopause two to three years earlier than the western populations [20] and these differences can be on account of environmental and genetic factors. Similarly age at menarche is also influenced by both genetic and environmental factors [21]. Heritability of age at natural menopause has been also studied [22]. Genome-Wide Association Studies (GWAS) have reported genetic determinants of age at menarche and age at natural menopause. He and Murabito [23] reviewed such studies and found more than 30 novel gene loci for age at menarche and 17 for age at natural menopause.

The various associated symptoms of menopause are due to decline of estrogen production, while continued production of gonadotrophin hormones by the hypothalamus [24]. The resulted menopausal distress due to miss-match signals in the brain is divided into somatic, urogenital and psychological. The symptoms, the menopause status and the aging process are known to influence various aspects of women’s health including bone loss, urogenital atrophy, urinary tract infections and incontinence, increased cardiovascular risk, sexual dysfunction, and loss of skin elasticity [25,26]. The biological and other changes associated with menopause are almost universal, but not all postmenopausal women are known to be affected. The cross-cultural research on menopause finds differences in the incidence/prevalence and severity of various climacteric symptoms and these are known to vary among-and within various segments of human populations [27-30]. It has also been suggested that differences in symptom sensitivity or a tendency to under-report are due to lack of education or else embarrassment among women [31]. Studies on prevalence of menopause symptoms are scarce from the state of Himachal Pradesh

Menarche is a critical biological reproductive maturity marker that marks the time of onset of menstruation. Age at menarche varies among individuals and mean age at menarche varies among various cohorts of a population and also among human populations. The age at menarche among the Western countries was about 15.3 years around 1840 and in the early 1980s it averaged around 12.8yrs [32]. A review based on studies from 67 countries published between the 1960s and the 1990 reported the mean menarche age of 13.53 years [9]. Anderson and Must [33] reported that in the USA, age at menarche dropped from 12.75 yrs in the 1960s to 12.5 yrs in the 1990s and to 12.3 yrs in the 2000s. Menarche among German girls occurred at a median age of 12.8 years [34]. Secular trends in age at menarche are well known. However, in recent years the onset of menarche has not decreased further and ranges between 12.5 and 13.0 years in most other European countries and the USA [35-37]. In developed countries this downward trend has ceased [38] or reversed [39].

Among non-European populations, a three generational study in Taiwan [40] showed significant decreased in age at menarche over these generations. In India too, socioeconomic and population differences were observed for mean age at menarche [41]. During 1980s median age at menarche in Northwest India was 13.2 years [41]. Even studies conducted in Northwest India from 1990-2010 reported mean/median age at menarche between 12 to 13.6 years [42]. Most of the studies were done middle or lower middle socioeconomic samples. The interval between age at menarche and age at menopause (reproductive life span) has implications for population structure and fertility dynamics. The downward trend in age at menarche world may have implications for the reproductive health and wellbeing of women and little is known about their association among populations living in different ecological settings.

Understanding of the relationship between ages at menarche and menopause may help in the improvement in planning preventive strategies and quality of life. Comparison of fertility trends in human populations has revealed that women who have a later age at menarche also have an earlier age of menopause and there is negative correlation between age at menopause and age at menarche [43]. Forman et al [44] reviewed literature on association between age at menarche and age at menopause and found that 12 out of 36 studies reported significant association between them. Hardy and Kuh [45] and Rodstrom et al. [46] found direct correlation between early menarche and early menopause. Dorjgochoo et al. [47] found direct correlation with between late menarche (mean age 15.2yrs) and late menopause (mean age 49.2 years) in cohort of Chinese women born 1930-1960. Both direct association [48-50] and inverse association [51] has been reported between age at menarche and age at menopause. The majority of studies have reported null relationship between age at menarche and age at menopause [44]. In view of contradictory reports, there is need to test this association in different populations of different nationalities living in different cultural settings.

Population studies have demonstrated an increased risk of earlier natural menopause among nulliparous vesus parous or a trend towards a delay in menopause with increase in number of live births [50,52-55]. Reproductive span of women is an important indicator of fertility levels of a population and also to understand women’s/ family’s reproductive planning and decision to end reproduction which is socially and culturally influenced. Over the years in India, a gradual increase in age at marriage among women and decrease in age at which they seek sterilization indicate that reproductive span is narrowing. Oral contraceptives and menstrual cycle characteristics appear to be associated with age at menopause [56,57]. So even if contraceptives are used by females, the number of livebirths may be associated with age at menopause and this aspect needs to be explored further. In view of these observations, number of livebirths may also be associated with age at menopause and this aspect requires exploration, which this study proposed to study.

The present study was undertaken with postmenopausal women of a rural population in Shimla to investigate menopausal characteristics, ages at menarche and menopause, and number of livebirths with the following specific aims and objectives: 1) To investigate the mean age at menopause; 2) To study incidence and pattern of various menopausal characteristics by using a standardized menopause rating scale; and 3) To study relationship of age of menarche with number of live births at their completion of their reproductive span. In view of the theoretical background given in the previous text, the present study also proposed to test the following hypotheses associated with menarche and menopause: 1) Women having an early age of menarche would have earlier menopause than those having late age of menarche; 2) women with earlier age at menarche would have fewer livebirths than women with later age at menarche; 3) since parity and age of menopause reported to be associated and assuming this to be true the study proposed to test that women having more number livebirths would have later age of menopause than women having fewer number of livebirths.

Materials and Methods

The materials for this study consisted of 75 postmenopausal women aged between 45-65 years with mean of 52.15 years and standard deviation of 4.68 years. They belonged to three villages around Shimla: Sangti, Neri and Chaeli, in the state of Himachal Pradesh. The ever-married women who had completed their fertility period were interviewed. Since the study was done in small villages and all the eligible females who agreed to participate were included in the study, so no sampling procedures were required. An interview schedule was designed and was used to get the detailed reproductive history of these women. The information was later checked with their husbands and elderly members of the family. The interview schedule included the following characteristics: Demographic information about fertility, mortality, morbidity, marriage and menopause was the key characteristics considered. Age at menarche and menopause were determined by the retrospective recall method. The reported age at menarche did suffer from recall bias since there was huge recall interval. But this bias held good for all the women respondents of this study and so the biased reporting was random and not systemic. The inclusive criteria were that the family should have been the permanent resident of the village and postmenopausal women. The excluding criteria was that a household where there was a second premenopausal wife and no information on first wife was available was excluded.

Scales to measure menopausal or climacteric symptoms in a standardized way have been developed and are widely accepted. The Menopause Rating Scale (MRS) that measures health related quality of life [56] has been used for this study. This scale has been extensively used in epidemiological studies across cultures and validated to assess the severity of menopausal symptoms. The MRS asks: “Which of the following symptoms apply to you at this time?” and uses a Likert Scale of responses for each symptom: none, mild, moderate, severe very sever. The MRS is subdivided into different symptoms; each of which is scored on a scale from “0” (no complaints) to “4” (very severe symptoms). The questionnaire was first translated into Hindi language. A pilot study was done before proceeding for the field work to validate the translated MRS questionnaire schedule. During the pilot study, it was noted that women experienced difficulties in understanding the terms and rating the scale themselves. So as to minimize these problems, face-to-face interviews were done rather than using self-administered questionnaire. All questions were asked in Hindi language. The recall error may be higher among older women. The data so collected were analyzed statistically using SPSS18 and the various tools used for analysis are explained in the results section. No distinctions were made between prevalence and incidence terms and were used interchangeably in this study

Results

83% of the women had menarche between 10-15 years while 17% had at or later than 16 years. Mean age at menarche was 14.23 yrs. with standard deviation of 1.75 years. Mean age at natural menopause was 45.35 yrs and standard deviation of 2.75 years. The mean natural reproductive span among the present sample of women was 31.23 years.

Climacteric symptoms

The results of the descriptive statistics of various menopausal symptoms have been presented in Table 1. About 85% of the postmenopausal women suffered from some climacteric symptom. The most common menopausal symptoms were muscle or joint pain (67%), headache (61%), rapid heartbeat (59%) and fatigue (59%). Prevalence of vaginal atrophy, urinary symptoms, uterine bleeding was about 30% or less, while that of depression, headache, tension, tiredness and breast pain was about 50% or higher. Average total sum of scores of MRS in the present sample was 19.43 with standard deviation of 15.5. They were reluctant to talk about sexual behavior, but the most common narrative that emerged was that rather than menopausal symptoms, other concerns had greater effect on sexual functioning (Table 1).

Table 1: Mean and Standard Deviation of frequency and percentage of various climacteric symptoms.

Sno

Climacteric / symptom

None

0

Mild

1

Moderate

2

Severe

3

Very severe

4

Vasomotor symptoms

 

1

 

Hot flush

 

 

Mean±SD

0.71±1.08

 

N

46

14

8

5

2

(%)

61.3

18.7

10.7

6.7

2.7

 

2

 

Night Sweating

 

 

Mean±SD

0.91±1.33

 

N

43

14

8

2

8

(%)

57.3

18.7

10.7

2.7

10.7

Vaginal symptoms

 

3

 

Uterine prilayers (bleeding)

 

 

Mean±SD

0.47±0.84

 

N

55

7

11

2

0

(%)

73.3

9.3

14.7

2.7

0

 

4

 

Vaginal atrophy

 

 

Mean±SD

0.63±1.11

 

N

51

11

7

2

4

(%)

68.0

14.7

9.3

2.7

5.3

Psychosomatic symptoms

 

5

 

Rapid heart beat

 

 

Mean±SD

1.16±1.16

 

N

31

15

15

14

0

(%)

41.3

20.0

20.0

18.7

0

 

6

 

Numbness

 

 

Mean±SD

0.85±0.97

 

N

36

19

15

5

0

(%)

48.0

25.3

20.3

6.7

0

 

7

 

Irritability

 

 

Mean±SD

0.93±1.07

 

N

35

19

13

7

1

(%)

46.7

25.3

17.3

9.3

1.3

 

8

 

Fatigue/Tiredness

 

 

Mean±S.D

1.21±1.24

 

N

31

15

13

14

2

(%)

41.3

20.0

17.3

18.7

2.7

 

9

 

Headache

 

 

Mean±SD

1.12 ± 1.14

 

N

29

21

14

9

2

(%)

38.7

28.0

18.7

12.0

2.7

 

10

 

Sleep disturbance

 

 

Mean±SD

1.25±1.45

 

N

35

12

12

6

10

(%)

46.7

16.0

16.0

8.0

13.3

 

11

 

Pressure or high stress

 

 

Mean±SD

1.25±1.33

 

N

32

13

14

11

5

(%)

42.7

17.3

18.7

14.7

6.7

 

12

 

Muscle or joint pain

 

 

Mean±SD

1.60±1.48

 

N

25

15

10

11

12

(%)

33.3

20.0

16.0

14.7

16.0

 

13

 

Faint

 

 

Mean±SD

0.92±1.30

 

N

43

12

8

8

4

(%)

57.3

16.0

10.7

10.7

5.3

 

14

 

Breast pain

 

 

Mean±SD

0.87±1.19

 

N

43

11

12

6

3

(%)

57.3

14.7

16.0

8.0

4.0

Psychological symptoms

 

15

 

Depression

 

 

Mean±SD

0.97±1.17

 

N

37

16

11

9

2

(%)

49.3

21.3

14.7

12.0

2.7

 

16

 

Tension

 

 

Mean±SD

1.12±1.26

 

N

32

19

12

8

4

(%)

42.7

25.3

16.0

10.7

5.3

 

17

 

Forgetful

 

 

Mean±SD

1.01±1.26

 

N

39

12

11

10

3

(%)

52.0

16.0

14.7

13.3

4.0

 

18

 

Poor concentration

 

 

Mean±SD

1.00±1.25

 

N

41

8

13

11

2

(%)

54.7

10.7

17.3

14.7

2.7

Urinary symptoms

 

19

 

Dysuria (difficult/painful urination)

 

 

Mean±SD

0.48±1.02

 

N

58

5

7

4

1

(%)

77.3

6.7

9.3

5.3

1.3

 

20

Increased urinary frquency

 

 

Mean±SD

0.49±0.84

 

N

53

9

11

2

0

(%)

70.7

12.0

14.7

2.7

0

 

21

 

Urine leak

 

 

Mean±SD

0.48±0.88

 

N

55

7

10

3

0

(%)

73.3

9.3

13.3

4.0

0

Association between Age of Menarche, Menopause and Number of Live Births

Hypothesis 1: Women having an early age of menarche would have an early age of menopause than those having late menarche

The results are presented in Table 2.

Table 2: Age at menopause in relation to age at menarche: One way ANOVA.

Age at Menarche

N

Age at Men

opause

F

P ( two-tailed)

Mean

SD

Less than 13

25

44.84

1.49

 

 

2.032

 

 

.139

Between 13-15

36

45.25

3.33

More than 15

13

46.69

2.69

The table shows that women having lower age at menarche had early age at menopause and age at menopause increased with increase in age at menarche. The null hypothesis (H0: µ1 = µ2 = µ3) that mean ages at menopause among three groups with varying ages at menarche was equal was tested to find whether differences were significant or not. Table 2 showed that null hypothesis was not clearly rejected as F value was not significant by a two-tailed test. These results showed that the proposed hypothesis was not fully supported by the present data, despite there were some indications to that effect.

Age at Menarche with Number of Live births

Results of analysis testing number of live births with reference to age at menarche are presented in Table 3.

Table 3: Live Births in relation to age at menarche: One way ANOVA.

Age at menarche

N

Live Birth

s

F

P ( two-tailed)

Mean

SD

Less than 13

26

2.38

.98

 

 

4.442

 

 

.015

Between 13-15

36

2.47

1.28

More than 15

13

3.62

1.85

The table shows that women who had early menarche had less number of live births than those

who had later menarche. The null hypothesis that mean numbers live births among three groups of mothers arranged according to their ages at menarche were same (H0: µ1 = µ2 = µ3) was significantly rejected by the F-test. Since there were significant differences, the multiple comparisons were made by Scheffes’ and Tukey’s tests, and results are presented in Tables 4 and 5. The tables show that significant differences in number of livebirths with respect to age at menarche were observed when comparison was made among women who had age at menarche later than 15 years vis-à-vis with other two groups and not between <13 and 13-15. These results indicate that age at menarche might have some association with number of livebirths.

Table 4: Live Births in relation to age at Menarche: Multiple comparisons by Scheffes test.

Dependent variable

 

(I)

 

(J)

Mean difference (I-J)

 

Std. error

P

(two-tailed)

95% Confidence Level

Lower bound

Upper bound

 

 

 

 

Live Births

<13

13-15

-.088

.335

.966

-.93

.75

 

>15

-1.231*

.443

.025

-2.34

-.12

13-15

<13

.088

.335

.966

-.75

.93

 

>15

-1.143*

.422

.030

-2.20

-.09

>15

<13

1.231*

.443

.025

.12

2.34

 

13-15

1.143*

.422

.030

.09

2.20

Table 5: Live Births in relation to age at Menarche: Multiple comparisons by Tukey (HSD) test.

Dependent variable

 

(I)

 

(J)

Mean difference (I-J)

 

Std. error

P

(two-tailed)

95% Confidence Level

Lower bound

Upper bound

 

 

 

 

Live Births

<13

13-15

-.088

.335

.963

-.89

.71

 

>15

-1.231*

.443

.019

-2.29

-.17

13-15

<13

.088

.335

.963

-.71

.89

 

>15

-1.143*

.422

.023

-2.15

-.13

>15

<13

1.231*

.443

.019

.17

2.29

 

13-15

1.143*

.422

.023

.13

2.15

Relationship of Age at Menopause with Number of Livebirths

Hypothesis 3: Women having larger number livebirths would have late menopause than women having less number of livebirths.

Results of analysis testing number of livebirths with reference to age at menopause are presented in Tables 6. The table shows that women who had 0-3 number of live births had earlier age at menopause than those who had 4-5 live births; but such conclusion can be drawn from the third category of women having more than 6 live births. The null hypothesis H0: µ1 = µ2 = µ3 was also not rejected by F-test (Table 6).

Table 6: Age at menopause in relation to live births: One way ANOVA.

Live births

N

Mean

S.D

F

P ( two-tailed)

0-3

57

45.21

2.53

 

 

.732

 

 

.485

4-5

14

46.14

3.80

>6

3

44.67

0.58

The proposed hypothesis was not fully supported by the present data though there is some indication to that effect. So a new hypothesis may be proposed that women with intermediate fertility category having 4-5 livebirths had later age of menopause than women having less than three livebirths.

Discussion

Menopausal problems/symptoms

In the present study, prevalence of menopausal symptoms was 85% and similar prevalence rate has been reported from many other populations, for example among Nigerian population, reported prevalence is 84.5% [58]. According to WHO [57] hot flushes and night sweats are the most common symptoms associated with menopause, but hot flushes prevalence in the present sample was moderate 39%. Since difference between flushing and night sweating is the time of the day when these occur and both are caused by same factors, their prevalence rate is similar. It has been reported that women suffering from hot flushes range between 15.1% and 61% [59,60]. Menopausal symptom frequency and severity have been reported to vary among different racial and ethnic groups [13,61-63]. In Abadan (Nigeria), joint and muscular discomfort has been reported as the most common symptom (59%) followed by physical and mental exhaustion sexual problems (40%) and 39% prevalence of hot flushes [64]. Among the Japanese and Chinese women, the prevalence of hot flushes and night sweats has been reported to be lower than the women from the European ancestry [12,65]. Haines et al. reported lowest prevalence of hot flushes (5%), and very high prevalence of body and joint pains (93%) among Indonesians, Vietnamese (96%) and Koreans (76%) women [66]. However there are contradictory reports. For example, among the Thai women aged 45-65 years, Peeyananjarassri et al. reported the prevalence of the night sweats, hot flushes, and vaginal dryness as 20.8%, 36.8% and 55.3%, respectively [67]. In the present study, prevalence of body/ joint pains and vaginal dryness was lower than those in Southeast Asian populations.

According to Gold et al. African-American women reported more vasomotor symptoms and vaginal dryness and less urine leakage and sleeping difficulty than the Caucasians [12]. They further reported that the Hispanic women experienced higher frequency of urine leakage, vaginal dryness, heart pounding, and loss of memory than the Caucasians. Palacois et al. also found that the frequency of vasomotor symptoms varies widely depending on the geographical region, selection of criteria, and method of symptom identification [68]. They analyzed various databases reported in different, large, epidemiological studies, and found that the prevalence of such symptoms ranged from 74% of women in Europe, 36-50% in North America, 45-69% in Latin America and 22-63% in Asia. There are many etiological theories, both biological and socio-cultural, regarding the occurrence of psychological symptoms in menopausal women. Obermeyer and Sievert invoked cultural specific symptoms to relate the reported nuances of the psychological symptoms. The various factors include differences in body size, hormone levels, socioeconomic status, smoking, diet, physical activity and psychological factors [69-71].

Concerns about the different methodologies used by investigators, language problems to understand medical terminology included translated terms and weakness of the research designs to assess the menopausal experiences have been expressed [72-74]. The use of uniform rating scale facilitates proper evaluation of the symptoms of menopause across various cultures. It has been observed that generally, women from developing countries, including those of the present study, tend to view menopause and its symptoms as a natural process that does not require medical care, so they are less aware about the health-related issues of menopause. Moreover culture of silence prevented them from seeking health care despite the fact that Shimla has a tertiary level hospital under medical college of Shimla.

Association between age at menarche and age at menopause

The results of the present study are consistent with the hypothesis of association between age at menarche and age at menopause. The women who had early menarche had early menopause and those with late menarche had late menopause. There are inconsistent reports on this association, varying from no association, positive association and inverse relationship and these are reviewed in the introduction part of this paper.

Thomas et al. [9] observed an increase in the average number of reproductive years (subtracting age at menarche from age at natural menopause), from 36.1 years among women born between 1915 and 1919 to 37.7 years among the 1935-1939 cohort (p≤0.0001). In present study, mean natural reproductive life span has been found to much lower than the women from the European ancestry. Other Indian studies also reports similar natural reproductive life span. It should be further explored whether it has something to do with early age at marriage. The present study also shows that women who had early menarche had lower number of live births than those who had later menarche.

Is Age at menopause among Indians lower than the western populations?

The databases published in various journals reporting mean ages at menopause of different populations across the globe were reanalyzed to study the significance of differences among them and the results are presented in Table 7.

Table 7: Mean and Standard deviation (SD) of mean ages at menopause among populations of different nationalities.

Region

N

Mean

yrs

SD

Range

yrs

ANOV

A

F

Sig.

India (South Asia)

48

46.35

1.66

42.56 -

49.36

 

 

 

 

 

 

 

23.408

 

 

 

 

 

 

 

.000

North & South East

Asia

19

48.80

1.50

44.00 -

51.28

Europe

19

50.58

.88

48.70 -

52.10

USA

11

49.39

1.26

47.50 -

51.40

Latin America

10

46.82

2.24

42.30 -

50.40

Middle East

18

47.85

1.15

45.80 -

50.40

Africa

9

48.33

1.01

46.16 -

49.60

Total

134

47.91

2.09

42.30 -

52.10

Since the number of studies is large (134 studies) and data as such has not been reported in this paper, so their references have not been given for brevity. Analysis of Variance (ANOVA) revealed significant differences in the mean ages of menopause across populations from different nationalities/ geographical regions. These differences among populations in their mean ages of menopause may be attributed to the factors like geography and race, food habits, occupations, parity, marital status, age at menarche and socio-economic factors and genetics. Income,education and the husband’s occupational category have been found to be associated with menopause [75]. When compared with other population, the mean age of menopause in the present sample comes around the mid value. Indian populations have relatively lower mean age at menopause than the other populations from Southeast Asian and Europe by about 2 years. Median age at menopause among the European populations was around 51 years, being about 4 years higher than that in India. Palacois et al. [7] by searching electronic databases of MEDLINE (1966- October 2009) and EMBASE (1975-October 2009) reported median age at menopause in Europe ranges from 50.1 to 52.8 years, in North America from 50 to 51.4 years, in Latin America from 43.8 to 53 years and in Asia from 42.1 to 49.5 years. McKnight et al. [76] found no significant differences in age at menopause between the White and the Black women after making adjustments for covariates, but women from the south (Who had greater proportions of black than white women) had earlier menopause than from the North of the USA.

Studies in western populations suggest that the age at menopause increased in recent decades [13-15], and this shift may be related to changes of socioeconomic conditions and lifestyle, particularly among young women. Nichols et al. [77] in their study on 22,774 American women born between 1910 and 1969 found that the mean age at natural menopause increased from 49.1 years for those born in 1915 1919 to 50.5years for those born in 1935-1939. However, these results were not supported by Pakarinen et al. [1] who studied a population based random sample of 7828 white women from Finland and found no evidence of a secular trend towards a later age at menopause in the last 25years. McKinlay [78] in an overview of population based studies reported that there was no evidence of any secular trend in age at menopause.

In any population, there would be women having early, late or intermediate age of menopause. There are inter-population differences in frequency distribution of such women. For example, it has been reported [79] that 11.7% of the postmenopausal Saudi Arabia women had menopause after the age of 55 years (with mean of 58.9 yrs) compared with 5% in U.K. and USA [80] and 3.5% in Finland [81]. The Polish studies by Kaczmarek [50] showed that lower socio-economics of women might contribute to the earlier median age at menopause.

Association of age of menarche and menopause with Parity/number of livebirths

Results of the present study show that both age at menarche and menopause are associated with number of livebirths. The association between menarche and livebirths may be statistical due to association between age at menarche and age at menopause; lower the age of menarche would follow lower age at menopause and vice versa. Age of menopause was clearly delayed with increase in number of live births in the present study. These results are interesting and needs further examination. However, it has been known that estrogen hormone is an important factor in follicle survival. Higher levels of estrogen during pregnancy are known to inhibit follicular atresia [82]; the latter (i.e. atretic follicles) are known to decrease estrogen production [83]. During lactation, estrogen levels remain low, resulting in promoting apoptotic cell loss, and thus pregnancy delays onset of menopause [82]. The smoking and nulliparity have been reported to be associated with early menopause [55].

Conclusions

There are indications of association between early age at menarche and early age of menopause. Fertility performance of women was associated with mean menarche and menopause ages. Indian women have lower mean age at menopause than the European and South Asian women. Prevalence of body/joint pains was highest followed by accelerated heart beat and fatigue, while lowest prevalence was for urinary and vaginal problems.

References

1. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson F. Accelerated disappearance of ovarian follicles in mid-life: N-implications for forecasting menopause. Hum Reprod. 1992; 7: 1342-1346.

2. Gougeon A. Regulation of ovarian follicular development in primates: Facts and hypotheses. Endocr Rev. 1996; 17: 121-155.

3. Peccei JS. A critique of the grandmother hypotheses: Old and new. Am J Hum Biol. 2001; 13: 434-452.

4. Lahdenpera M, Lummaa V, Russell AF. Selection on male longevity in a monogamous human population: Late-life survival brings no additional grandchildren. J Evol Biol. 2011; 24: 1053-1063.

5. Morton RA, Stone JR, Singh RS. Mate choice and origin of menopause. PLoS Comput Biol. 2013; 9.

6. Williams GC. Pleiotropy, natural selection, and the evolution of senescence. Evolution. 1957; 11: 398-411.

7. Broekmans FJ, Soules MR, Fauser BC. Ovarian aging: Mechanisms and clinical consequences. Endocr Rev. 2009; 30: 465-493.

8. Morabia A, Costanza MC. World Health Organization Collaborative Study N. International variability in ages at menarche, first livebirth, and menopause. Am J Epidemiol 1998; 148: 1195-1205.

9. Thomas F, Renaud F, Benefice E, de Meeus T, Guegan JF. International variability of ages at menarche and menopause: Patterns and main determinants. Human Biology 2001; 73: 271-290.

10. Henderson KD, Bernstein L, Henderson B, Kolonel L, Pike MC. Predictors of the timing of natural menopause in the multiethnic cohort study. American Journal of Epidemiology. 2008; 167: 1287-1294.

11. Flint MP. Secular trends in menopause age. J. Psychosom Obstet Gynecol. 1997; 18: 65-72.

12. Gold EB, Sternfeld B, Kelsey JL, Brown C, Mouton C, Reame N, et al. Relation of demographic and lifestyle factors to symptoms in a multiracial/ethnic population of women 40-55 years of age. American Journal of Epidemiology. 2000; 152: 463-473.

13. Dratva J, Gomez Real F, Schindler C, Ackermann-Liebrich U, Gerbase MW, Probst-Hensch NM, et al. Is age at menopause increasing across Europe? Results on age at menopause and determinants from two population-based studies. Menopause. 2009; 16: 385-394.

14. Mishra GD, Cooper R, Tom SE, Kuh D. Early life circumstances and their impact on menarche and menopause. Womens Health. 2009; 5: 175-190.

15. Pakarinen M, Raitanen J, Kaaja R, Luoto R. Secular trend in the menopausal age in Finland 1997-2007 and correlation with socioeconomic, reproductive and lifestyle factors. Maturitas. 2010; 66: 417-422.

16. Liu P, Lu Y, Recker RR, Deng HW, Dvornyk V. Association analyses suggest multiple interaction effects of the methylene tetrahydrofolate reductase polymorphisms on timing of menarche and natural menopause in white women. Menopause. 2010; 17: 185-190.

17. Van Noord PA, Dubas JS, Dorland M, Boersma H, te Velde E. Age at natural menopause in a population-based screening cohort: the role of menarche, fecundity, and lifestyle factors. Fertility and Sterility. 1997; 68: 95-102.

18. Gold EB, Bromberger J, Crawford S, Samuels S, Greendale GA, Harlow SD, et al. Factors associated with age at natural menopause in a multiethnic sample of midlife women. American Journal of Epidemiology. 2001; 153: 865 874.

19. Kapur P, Sinha B, Pereira BM. Measuring climacteric symptoms and age at natural menopause in an Indian population using the Greene Climacteric Scale. Menopause. 2009; 16: 378-384.

20. Kriplani A, Kaberi B. An overview of age of onset of menopause in northern India. Maturitas. 2005; 52: 199-204. 21. Sharma K. Genetic basis of human female pelvic morphology: A twin study. Am. J. Phys. Anthropol. 2005; 117: 327-333.

22. Murabito JM, Yang Q, Fox C, Wilson PW, Cupples LA. Heritability of age at natural menopause in the Framingham Heart Study. J Clin Endocrinol Metab. 2005; 90: 3427-3430.

23. He C, Murabito JM. Genome-wide association studies of age at menarche and age at natural menopause. Molecular and Cellular Endocrinology. 2014; 382: 767-779.

24. Takahashi TA, Johnson KM. Menopause. Medical Clinics of North America. 2015; 99: 521-534.

25. Budakoglu II, Ozcan C, Eroglu D, Yanik F. Quality of life and postmenopausal symptoms among women in a rural district of the capital city of Turkey. Gynecological Endocrinology. 2007; 23: 404-409.

26. Chedraui P, Aguirre W, Hidalgo L, Fayad L. Assessing menopausal symptoms among healthy middle aged women with the Menopause Rating Scale. Maturitas. 2007; 57: 271-278.

27. Chim H, Tan BH, Ang CC, Chew EM, Chong YS, Saw SM. The prevalence of menopausal symptoms in a community in Singapore. Maturitas. 2002; 41: 275-282.

28. Waidyasekera H, Wijewardena K, Lindmark G, Naessen, T. Menopausal symptoms and quality of life during the menopausal transition in Sri Lankan women. Menopause. 2009; 16:164-170.

29. Rahman SA, Zainudin SR, Mun VL. Assessment of menopausal symptoms using modified Menopause Rating Scale (MRS) among middle age women in Kuching, Sarawak, Malaysia. Asia Pacific Family Medicine. 2010; 9: 5.

30. Chuni N, Sreeramareddy CT. Frequency of symptoms, determinants of severe symptoms, validity of and cut-off score for Menopause Rating Scale (MRS) as a screening tool: A cross-sectional survey among midlife Nepalese women. BMC Women’s Health. 2011; 11: 30.

31. Boulet MJ, Oddens BJ, Lehert P, Vemer HM, Visser A. Climacteric and menopause in seven south-east Asian countries. Maturitas. 1994; 19: 157 176.

32. Ducros A, Pasquet P. Evolution de l’âge d’apparition des premières règles (ménarche) en France. Biométrie Humaine. 13: 35-43.

33. Anderson SE, Must A. Interpreting the continued decline in the average age at menarche: Results from two nationally representative surveys of U.S. girls studied 10 years apart. J Pediatr. 2005; 147: 753-760.

34. Bau AM, Ernert A, Schenk L, Wiegand S, Martus P, Gruters A, et al. Is there a further acceleration in the age at onset of menarche? A cross-sectional study in 1840 school children focusing on age and bodyweight at the onset of menarche European Journal of Endocrinology. 2009; 160; 107-113.

35. Danke-Hopfe H. Menarcheal age in Europe. Yearbook of Physical Anthropology. 1986; 29: 81-112.

36. Ostersehlt D, Danke-Hopfe H. Changes in the age at menarche in Germany: Evidence for a continuing decline. American Journal of Human Biology. 1991; 3: 647-654.

37. Cole TJ. Secular trends in growth. Proceedings of the Nutrition Society. 2000; 59: 317-324.

38. Tryggvadottir L, Tulinius H, Larusdottir M. A decline and a halt in mean age at menarche in Iceland. Ann Hum Biol. 1994; 21: 179-186.

39. Dann TC, Roberts DF. Menarcheal age in University of Warwick young women. J Biosoc Sci. 1993; 25: 531-538.

40. Chang SR. Age at menarche of three-generation families in Taiwan. Ann Hum Biol. 2008; 35: 394-405

41. Sharma K. Age at menarche in northwest Indian females and a review of Indian data. Ann Hum Biol. 1990; 17:159-162.

42. Talwar I, Sharma K, Kapur S. Growth trends in body, fat, circumferential and physiological traits during adolescence among Rajput females of Theog, Shimla District (Himachal Pradesh), India. Annals of Human Biology. 2010; 37: 536-553.

43. Frisch RE. Body fat, menarche, fitness and fertility. Hum Reprod. 1987; 2: 521-533.

44. Forman MR, Mangini LD, Thelus-Jean R, Hayward MD. Life-course origins of the ages at menarche and menopause. Adolesc Health Med Ther. 2013; 18: 1-21.

45. Hardy R, Kuh D. Reproductive characteristics and the age at inception of the perimenopause in a British National Cohort. American Journal of Epidemiology. 1999; 149: 612-620.

46. Rodstrom K, Bengtsson C, Milsorm I, Lissner L, Sundh V, Bjourkelund C. Evidence for a secular trend in menopausal age: A population study of women in Gothenburg. Menopause. 2003; 10: 538-543.

47. Dorjgochoo T, Kallianpur A, Gao YT, Cai H, Yang G, et al. Dietary and lifestyle predictors of age at natural menopause and reproductive span in the Shanghai Women’s Health Study. Menopause. 2008; 15: 924-933.

48. Ozdemir O, Col M. The age at menopause and associated factors at the health center area in Ankara, Turkey. Maturitas. 2004; 49: 211-219.

49. Parazzini F. Determinants of age at menopause in women attending menopause clinics in Italy. Maturitas. 2007; 56: 280-287.

50. Kaczmarek M. The timing of natural menopause in Poland and associated factors. Maturitas. 2007; 57: 139-153.

51. Van Keep PA, Brand PC, Lehert P. Factors affecting the age at menopause. J Biosoc Sci Suppl. 1979; 6: 37-55.

52. Soberon J, Calderon JJ, Goldzieher JW. Relation of parity to age at menopause. Am J Obstet Gynecol. 1966; 96: 96-100.

53. Jeune B. Parity and age at menopause in a Danish sample. Maturitas. 1986; 8: 359-365.

54. Whelan EA, Sandler DP, Mc Connaughey DR, Weinberg CR. Menstrual and reproductive characteristics and age at natural menopause. Am J Epidemiol. 1990; 131: 625-632.

55. Meschia M, Pansini F, Modena AB, de Aloysio D, Gambacciani M, et al. Determinants of age at menopause in Italy: results from a large cross sectional study. ICARUS Study Group. Italian Climacteric Research Group Study. Maturitas. 2000; 34: 119-125.

56. Ortiz AP, Harlow SD, Sowers M, Nan B, Romaguera J. Age at natural menopause and factors associated with menopause state among Puerto Rican women aged 40-59 years, living in Puerto Rico. Menopause. 2006; 13: 116-124.

57. Harlow BL, Signorello LB. Factors associated with early menopause. Maturitas. 2000; 35: 3-9.

58. Cooper GS, Baird DD, Darden FR. Measures of menopausal status in relation to demographic, reproductive, and behavioral characteristics in a population based study of women aged 35-49 years. Am J Epidemiol. 2001; 153: 1159 1165.

59. Greene JG. Measuring the symptom dimension of quality of life: General and menopause-specific scales and their subscale structure. In Schneider HPG, editor: Hormone replacement therapy and quality of life. The Parthenon Publishing Group: Boca Raton, London, New York, Washington. 2002; 35-43.

60. Olaorun FM, Lawovin TO. Experience of menopausal symptoms by women in an urban community in Ibadan, Nigeria. Menopause. 2009; 16: 822-830.

61. WHO. Research on menopause (WHO Report series.No.866). World Health Organization, Geneva. 1996.

62. Fuh JL, Wang SJ, Lu SR, Juang KD, Chiu LM. The Kinmen women-health investigation (KIWI): a menopausal study of a population aged 40-54. Maturitas. 2001; 39: 117-124.

63. Obermeyer CM, Schulein M, Hajji N, Azelmat M. Menopause in Morocco: symptomatology and medical management. Maturitas. 2002; 41: 87-95.

64. Castelo-Branco C, Blumel JE, Chedraui P, Calle A, Bocanera R, Depiano E, et al. Age at menopause in Latin America. Menopause. 2006; 13: 706-712.

65. Avis NE, Stellato R, Crawford S, Bromberger J, Ganz P, Cain V, et al. Is there a menopausal syndrome? Menopausal status and symptoms across racial/ ethnic groups. Soc Sci Med. 2001; 52: 345-356.

66. Haines CJ, Xing SM, Park KH, Holinka CF, Ausmanas MK. Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxy progesterone acetate: the Pan-Asia Menopause (PAM) study. Maturitus. 2005; 52: 264-276.

67. Peeyananjarassri K, Cheewadhanaraks S, Hubbard M, Zoa Manga R, Manocha R, Eden J. Menopausal symptoms in a hospital-based sample of women in southern Thailand. Climacteric. 2006; 9: 23-29.

68. Palacios S, Henderson VW, Siseles N, Tan D, Villaseca P. Age of menopause and impact of climacteric symptoms by geographical region. Climacteric. 2010; 13: 419-428.

69. Obermeyer CM, Sievert LL. Cross-cultural comparisons: Midlife, aging, and menopause. Menopause. 2007; 14: 663-667.

70. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: study of women’s health across the nation. Am J Public Health. 2006; 96: 1226-1235.

71. Melby MK, Lampl M. Menopause, a biocultural perspective. Annual Review of Anthropology. 2011; 40: 53-70.

72. Kaufert PA, Gilbert P, Hassard T. Researching the symptoms of menopause: an exercise in methodology. Maturitas. 1988; 10: 117-131.

73. Avis NE, McKinlay SM. A longitudinal analysis of women’s attitudes toward the menopause: results from the Massachusetts Women’s Health Study. Maturitas. 1991; 13: 65-79.

74. Zeserson JM. How Japanese women talk about hot flushes: implications for menopause research. Med Anthropol Q. 2001; 15: 189-205.

75. WHO. Research on the Menopause, WHO Technical Report Series 670. World Health Oragnization, Geneva. 1981.

76. McKnight KK, Wellons MF, Sites CK, Roth DL, Szychowski JM, Halanych JH, et al. Racial and regional differences in age at menopause in the United States: Findings from the reasons for geographic and racial differences in stroke (REGARDS) study. American Journal of Obstetrics and Gynecology. 2011; 205: 353, e351-358.

77. Nichols HB, Trentham-Dietz A, Hampton JM, Titus-Ernstoff L, Egan KM, Willett WC, et al. Newcomb. From menarche to menopause: Trends among us women born from 1912 to 1969. Am J Epidemiol. 2006; 164: 1003-1011.

78. McKinlay SM. The normal menopause transition: an overview. Maturitas. 1996; 23:137-145.

79. Greer W. Preprocessing histograms of age at menopause using the fast Fourier transform. Maturitas. 2003; 44: 267-277.

80. Stanford JL, Hartge P, Brinton LA, Hoover RN, Brookmeyer R. Factors influencing the age at natural menopause. J Chron Dis. 1987; 40: 995-1002.

81. Luoto R, Kaprio J, Uutela A. Age at natural menopause and sociodemographic status in Finland. Am J Epidemiol 1994; 139: 64-76.

82. Weinstein M, Gorrindo T, Riley A, Mormino J, Niedfeldt J, Singer B, et al. Timing of menopause and patterns of menstrual bleeding. Am J Epidemiol. 2003; 158: 782-791.

83. Kaipia A, Hsueh AJW. Regulation of ovarian follicle atresia. Annu Rev Physiol. 1997; 59: 349-363

Other Articles

Article Image 1

Ameliorative Effects of Phyllanthus muellerianus (Kuntze) Exell Roots Extracts on Hormonal Imbalances and Ovarian Histology in Letrozole-Induced Polycystic Ovary Syndrome in Rats

This study investigates the effects of Phyllanthus muellerianus roots extracts on hormonal levels and ovarian histology in a rat model of polycystic ovary syndrome (PCOS) induced by letrozole (LTZ). Female rats were treated with aqueous and ethanolic extracts of P. muellerianus at varying doses (30, 60, and 120 mg/kg bwt) for 21 days. Hormonal assays, including the measurement of serum estradiol, testosterone, luteinizing hormone (LH), and follicle-stimulating hormone (FSH) levels, were conducted using enzyme-linked immunosorbent assay (ELISA) kits. Results revealed a significant increase in estradiol levels in all treated groups compared to the positive control, while testosterone levels significantly decreased in all treated rats, indicating a potential estrogenic effect and androgen reduction. However, LH and FSH levels remained unaffected by the treatment. Histological examination of ovaries showed significant improvements in follicular development and structural integrity in rats treated with P. muellerianus, particularly at 30 mg/kg bwt of the aqueous extract, which demonstrated nearly complete restoration of normal ovarian architecture. These findings suggest that Phyllanthus muellerianus possesses potential therapeutic properties in modulating reproductive hormones and improving ovarian histology in a PCOS model, supporting its traditional use in the management of reproductive health disorders.

Arinze C. Chukwuezie¹, Oluwagbenga J. Ogunbiyi²*, Joseph Appah¹, and Emmanuel Enoh³


Article Image 1

Progesterone in Breast Cancer Angiogenesis

The involvement of steroid hormones in breast carcinogenesis is well established. Recent evidence suggests that angiogenesis can be regulated by hormones. Both oestrogen and progesterone have been implicated in the angiogenic process of hormone-dependent cancers, such as breast cancer. Vascular Endothelial Growth Factor (VEGF) is a growth factor involved in angiogenesis in breast cancer that is up-regulated by estrogens. In our study we evaluated the role of progesterone in the expression of this angiogenic growth factor commonly up regulated in breast cancer. Our findings indicate that progesterone activates an angiogenic pathway involving VEGF stimulation. The elucidation of specific angiogenic pathways promoted by progesterone can raise new therapeutic targets at least in a subset of breast cancers responsive to progesterone.

Monica C. Botelho¹,²,³*, Raquel Soares³,⁴ and Helena Alves¹


Article Image 1

A Decade of Social Fertility Preservation

The global phenomenon of deferment of conception has led to an increase in the age of sub fertile community and a growing demand for assisted reproductive techniques. Social fertility preservation can be considered a hedge against age-related decline in fertility and is considered as a form of elective self-donation; where healthy females collect then freeze their oocytes for autologous use at a later stage in life. From August 2005 to July 2014, 67 women presented for social fertility preservation at our institution. The mean age was 38.6±3.6 years. They were mostly single, nulliparous and professionals. They underwent a total of 128 cycles of In Vitro Fertilization (IVF) and 4 cycles of In Vitro Maturation (IVM). The number of oocytes frozen was 11.3±7.1. Only 5 women returned to achieve a pregnancy (7.5%). Embryo transfer of 4 patients did not reveal any live birth. It suggests that social fertility preservation after the age of 35 years is associated with a poor outcome. Social fertility preservation should be considered at an early reproductive age.

Nouf Alasmari¹, Atif Zeadna¹, Hananel Holzer¹, Weon-Young Son¹, William Buckett¹, Janet Takefman¹ and Togas Tulandi¹*


Article Image 1

Localized Drug Delivery in Prostate Cancer Treatment

Drug delivery to prostate through conventional route is associated with pharmacokinetics based and side effects related problems. Alternate localized drug delivery route is a prerequisite which may offers many advantages over oral route of drug delivery to prostate. In male reproductive system, Vas deferens forms a continuous system with prostate, so we discuss possibility of developing novel drug delivery system which may help to overcome with problems associated with the route of drug administration, including poor absorption, metabolic degradation, sub-threshold value of drug reaching the target tissue and non-specific drug distribution related side effects. And particularly, throwing light on an alternative drug delivery route may offer advantages to circumvent some of the above mentioned hurdles of oral drug administration. The current editorial promotes vas deferens as a local drug delivery route to prostate in conjunction with a concept of in-vivo self-assembly of multi component nanodrug carrier generated by a drug delivery system injected in the lumen of vas deferens

Pradeep K. Jha¹*, Rakhi Jha², Gnanasekar Sathish Kumar³, Santosh Gupta⁴ and Maidul Hossain⁵


Article Image 1

Maternal Plasma Levels of Antithrombin-III versus Inhibin-A in Prediction of Second Trimester Miscarriage

Objective: To study whether changes in maternal plasma thrombin inhibitor complex level and Inhibin-A are associated with second trimester miscarriages or not.

Design: Prospective study.

Setting: Tanta University Hospital.

Methods: The study included 200 asymptomatic pregnant women with singleton pregnancy of 15-20 weeks divided into two groups: 154 pregnant women with no history of abortion and 46 expectant women with a prior history of abortion. Each case was subjected to detailed obstetric and gynecological history, clinical examination, determination of gestational age, fetal viability, routine antenatal laboratory investigations, ultrasound examination and measurement of human Antithrombin-III and Inhibin-A.

Results: The mean values of maternal plasma levels of Inhibin-A and Antithrombin-III were significantly lower in patients with a history of abortion than those without a history of abortion. The area under Receiving Operating Characteristic (ROC) curve denoting sensitivity and specificity of maternal plasma levels of Inhibin-A compared to Antithrombin-III as a prognostic factor to miscarriage among pregnant women during the second trimester.

Conclusions: We concluded that Inhibin-A could be useful in monitoring of miscarriage in patients during the second-trimester pregnancy.

El-Gharib MN, El Sabae TM and Morad MA*


Article Image 1

Cesarean Scar Pregnancy Profile and Therapeutic Outcome: Case Series Design

Background: It is recognized that a Caesarean section presents one of the risk factors for ectopic pregnancies and placental pathologies (i.e., placenta prevue, placental abruption and placenta percreta) in the subsequent pregnancies.

Objectives: To study the incidence rate of scar pregnancy among admitted patient to ob/Gyn ward at latifa public hospital in Dubai. To study some associated factors Number of previous cesarean, parity, age of patients. To study therapeutic outcome using Methotroxate injection. Women admitted to the Hospital were of different parity status at the time of admission.

Methodology: A Retrospective records review of the caesarean scar pregnancy admitted to Latifa Hospital (Gynecology and pediatric governmental Hospital in Dubai) along the last 3 years has been recruited in the study, about 25 women age rang (20-49), cases been diagnosed as scar pregnancy at obstetrics /gynecology ward - Latifa public hospital, with positive history of previous single or multiple cesarean section. 19 cases have been went under Methotroxate injection therapy and follow up by BHCG and close clinical monitoring, about 8 cases refuse therapeutic intervention, most of the cases diagnosed on clinical base and upon admitting signs and symptoms which were mainly, bleeding in the first trimester, abdominal pain, spotting PV or asymptomatic diagnosed on routine pregnancy assessments, there is no loss of follow up of the cases yet 8 of the cases refused to receive Methotroxate injection, but no surgical treatment protocol applied to these cases . Surgery image and ultrasound were of no major role in diagnosis.

Results: The study revealed that about (16) 68% of the cases had positive history of three times and above cesarean section delivery, about (19) 76% of the cases were having multiparty of three and above, it was shown that about 60% of patients were in age group between ( 30-39). The study showed that about 64% of the case presented as bleeding in the first trimester while 20% presented either asymptomatic or simple abdominal pain and discovered on routine examination. The study revealed that about (16) 68% of the total cases have 3 more parity while only (2) 4% have 1 parity; the result showed that about (19) 76% of the total scar pregnancy cases were of the age group 30-39. As for the distribution of scar pregnancy cases according to number of cesarean section, it has been shown that (12) 66% of the total cases were of those who have history of 3 or more cesarean section while history of one CS where shown to be about (4) 16%. While the most common presenting features of scar pregnancy were shown to be bleeding in the first trimester equal to (14) 56% of the total cases and about (5) 20% were presented asymptomatically and discovered by routine investigation. Current study showed that about (8) 28% of the total cases refuse medication intervention and prefer to continue with follow up while (17) 72% received Methotroxate alone or with other medication of different doses regimen). For the outcome of management the study showed that about (9) 36% of scar pregnancy cases were responded by BHCG dropping but about (16) 60% of the cases have got bleeding, readmission and surgical evacuation and some of the got sever complications.

Conclusion: Though scar pregnancy is rare diagnoses, it has serious consequences in terms of morbidly and mortality (uterine rupture and life-threatening intraperitoneal hemorrhage during the first trimester of pregnancy) which can be avoided by early identification, accurate diagnostic and effective intervention procedures. Recommendation: Prevention and control of scar pregnancy can be achieved different level, like minimizing the frequency cesareans section program, raising index of suspension at high risk groups, earlier identification and intervention.

Isaac B, Hussain H*, Paulose L, Amro B, Lotfi G and Al Faisal W


Article Image 1

Toxoplasmosis Seropositivity and Male Sex Hormones

Background: Toxoplasmosis is a cosmopolitan disease with acute and chronic infections, caused by the obligate intracellular protozoan parasite Toxoplasma gondii that can infect a variety of cells in almost all warm blooded animals including humans.

The study aimed to determine the seroprevalence of T. gondii infection among males in Duhok city using ELISA (IgG and IgM).

The relationship between toxoplasmosis and reproductive hormones including testosterone, free testosterone, and Follicle Stimulating Hormone (FSH) levels and its association with male sterility were also investigated.

Mustafa Riadh Hussien¹*, Adel TM Al-Saeed¹ and Souzan H Eassa²


Article Image 1

Status of Artificial Insemination; Its Constraints and Estrous Synchronization in Ethiopia

Assisted reproductive technologies particularly artificial insemination (AI) and estrus synchronization are operated to enhance the genetic improvement of cattle. Estrus synchronization is one of the potential tools for the reproductive improvement of livestock. It is the manipulation of the estrus cycle or induction of estrus to bring a large percentage of groups of females into estrus at a short and predetermined time period. Estrus synchronization of fertile cows can be accomplished with various hormones; such as, progesterone, prostaglandin, gonadotropin releasing hormone (GnRH), follicle stimulating hormone (FSH) and luteinizing hormone (LH). These tools remain the most useful and widely applicable reproductive biotechnologies available for dairy cow operations. It is obvious that the AI service in Ethiopia has not been successful to improve reproductive performance of dairy industry. Artificial insemination service in Ethiopia has been given little or no emphasis at the federal and regional levels for long time though it is a widely practiced animal biotechnology all over the world. The most important constraints associated to estrous synchronization in Ethiopia are: inadequate resource in terms of inputs and facilities; absence of incentives and rewards to motivate technicians; lack awareness of this technology by animal producers; shortage of feed resources; cost of semen and synthetic hormones; cost of a bull (a self trained breeding technician), and lack of adequate transportation facilities. In general, incorporating a good management practice and selecting cows that have good body condition are the two most essential requirements for successful estrous synchronization and AI. Hence, the objective of this review is to assess the current status of artificial insemination; its constraints and estrous synchronization in Ethiopia.

Mebrate Getabalew¹ and Tewodros Alemneh²*